Company

Egetis Therapeutics AB

Headquarters: Stockholm, Sweden

Employees: 12

FSX: P0F +3.37%

Market Cap

€115.0 Million

EUR as of July 1, 2024

US$123.5 Million

Market Cap History

Egetis Therapeutics AB market capitalization over time

Evolution of Egetis Therapeutics AB market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Egetis Therapeutics AB

Detailed Description

Egetis Therapeutics AB (publ), a pharmaceutical drug development company, focuses on projects in late-stage development for the treatment of serious rare/niche diseases with unmet medical needs in the orphan drug segment. Its products pipeline includes Aladote, a drug to reduce the risk of acute liver injury associated with acetaminophen/paracetamol poisoning, which is in phase IIb/III clinical trial; and Emcitate, a drug for the treatment of MCT8 deficiency, a rare inborn error of thyroid hormone signaling that is in phase IIb/III clinical trial. The company was formerly known as PledPharma AB (publ) and changed its name to Egetis Therapeutics AB (publ) in December 2020. Egetis Therapeutics AB (publ) was incorporated in 2006 and is based in Stockholm, Sweden.

Top 1-year algo backtest: +227.67%

$10,000 in September 2023 would now be $32,767 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Stocks & Indices

Egetis Therapeutics AB has the following listings and related stock indices.


Stock: FSX: P0F wb_incandescent

Details

Headquarters:

Grev Turegatan 11c

Stockholm, 114 46

Sweden

Phone: 46 86 79 72 10

Fax: 46 86 63 57 25